These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Serum Fas in patients with Graves' ophthalmopathy as a marker of activity of the ocular inflammatory infiltration]. Myśliwiec J, Kretowski A, Stepień A, Okłota M, Kinalska I. Pol Merkur Lekarski; 2004 Oct; 17(100):368-70. PubMed ID: 15690704 [Abstract] [Full Text] [Related]
4. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids. Myśliwiec J, Kretowski A, Topolska J, Siewko K, Jakubczyk D, Szelachowska M, Mikita A, Kinalska I. Horm Metab Res; 2001 Dec; 33(12):739-43. PubMed ID: 11753760 [Abstract] [Full Text] [Related]
5. Serum L-selectin and ICAM-1 in patients with Graves' ophthalmopathy during treatment with corticosteroids. Myśliwiec J, Kretowski A, Szelachowska M, Topolska J, Mikita A, Kinalska I. Immunol Lett; 2001 Oct 01; 78(3):123-6. PubMed ID: 11578685 [Abstract] [Full Text] [Related]
6. Serum pro- and anti-inflammatory cytokines in patients with Graves' disease with ophthalmopathy during treatment with glucocorticoids. Myśliwiec J, Kretowski A, Szelachowska M, Mikita A, Kinalska I. Rocz Akad Med Bialymst; 1999 Oct 01; 44():160-9. PubMed ID: 10697431 [Abstract] [Full Text] [Related]
7. Interleukin 18 and transforming growth factor beta1 in the serum of patients with Graves' ophthalmopathy treated with corticosteroids. Myśliwiec J, Kretowski A, Stepień A, Mirończuk K, Kinalska I. Int Immunopharmacol; 2003 Apr 01; 3(4):549-52. PubMed ID: 12689659 [Abstract] [Full Text] [Related]
9. Serum gelatinases (MMP-2 and MMP-9) and VCAM-1 as a guideline in a therapeutic approach in Graves' ophthalmopathy. Myśliwiec J, Adamczyk M, Pawłowski P, Nikołajuk A, Górska M. Endokrynol Pol; 2007 Apr 01; 58(2):105-9. PubMed ID: 17578825 [Abstract] [Full Text] [Related]
10. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy. Nowak M, Siemińska L, Karpe J, Marek B, Kos-Kudła B, Kajdaniuk D. J Endocrinol Invest; 2016 Jan 01; 39(1):63-72. PubMed ID: 26062519 [Abstract] [Full Text] [Related]
11. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R, Braverman LE, Roti E. J Clin Endocrinol Metab; 1996 Aug 01; 81(8):2976-9. PubMed ID: 8768861 [Abstract] [Full Text] [Related]
18. Soluble CD40 and its ligand CD154 in patients with Graves' ophthalmopathy during combined therapy with corticosteroids and teleradiotherapy. Myśliwiec J, Waligórski D, Nikołajuk A, Górska M. Adv Med Sci; 2007 Aug 01; 52():104-8. PubMed ID: 18217399 [Abstract] [Full Text] [Related]
19. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. Colao A, Lastoria S, Ferone D, Pivonello R, Macchia PE, Vassallo P, Bonavolonta G, Muto P, Lombardi G, Fenzi G. J Clin Endocrinol Metab; 1998 Nov 01; 83(11):3790-4. PubMed ID: 9814448 [Abstract] [Full Text] [Related]